Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT02004041 | Proof of Concept of VLY-686 in Subjects With Treatment-Resistant Pruritus Associated With Atopic Dermatitis | PHASE2 | COMPLETED | 69 | — | — | Dec 10, 2013 | Feb 19, 2015 | Jun 11, 2024 | 5 | Germany |
Responses were measured on a 100-mm Visual Analogue Scale (VAS), where the left end point was marked "no itch" (0 mm) and in the right end point was marked "worst imaginable itch" (100 mm).
| Arm | Type | Description |
|---|---|---|
| VLY-686 | EXPERIMENTAL | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| VLY-686 | DRUG | - |
| Placebo | DRUG | - |
Inclusion Criteria: * Men and women ages 18 - 65 years, inclusive; suffering from atopic dermatitis with a SCORAD index at inclusion ≤80; with atopic lesions on arms, legs, trunk and neck; * Chronic pruritus with pruritus being actively present for at least 6 weeks prior to screening; * Males, non-...